NO20013678L - Alkynyl-holdige hydroksamsyre-derivater, deres fremstilling og deres anvendelse sommatriksmetalloproteinase(MMP)inhibitorer/TNF-<alfa>-konverteringsenzym(TACE)inhibitorer - Google Patents
Alkynyl-holdige hydroksamsyre-derivater, deres fremstilling og deres anvendelse sommatriksmetalloproteinase(MMP)inhibitorer/TNF-<alfa>-konverteringsenzym(TACE)inhibitorerInfo
- Publication number
- NO20013678L NO20013678L NO20013678A NO20013678A NO20013678L NO 20013678 L NO20013678 L NO 20013678L NO 20013678 A NO20013678 A NO 20013678A NO 20013678 A NO20013678 A NO 20013678A NO 20013678 L NO20013678 L NO 20013678L
- Authority
- NO
- Norway
- Prior art keywords
- mmp
- tnf
- summer
- alkynyl
- inhibitors
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15518499P | 1999-01-27 | 1999-01-27 | |
| US23803899A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/001864 WO2000044723A1 (en) | 1999-01-27 | 2000-01-27 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20013678D0 NO20013678D0 (no) | 2001-07-26 |
| NO20013678L true NO20013678L (no) | 2001-09-20 |
Family
ID=26852069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013678A NO20013678L (no) | 1999-01-27 | 2001-07-26 | Alkynyl-holdige hydroksamsyre-derivater, deres fremstilling og deres anvendelse sommatriksmetalloproteinase(MMP)inhibitorer/TNF-<alfa>-konverteringsenzym(TACE)inhibitorer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6358980B1 (no) |
| EP (1) | EP1147085B1 (no) |
| CN (1) | CN1178915C (no) |
| BR (1) | BR0007784A (no) |
| NO (1) | NO20013678L (no) |
| WO (1) | WO2000044723A1 (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02007291A (es) * | 2000-01-27 | 2002-11-29 | American Cyanamid Co | Metodo para preparar derivados de acido alfa-sulfonil hidroxamico. |
| CA2459380C (en) * | 2001-09-07 | 2010-11-23 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
| EP1440057A1 (en) * | 2001-11-01 | 2004-07-28 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| GB0216379D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
| AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| WO2004060875A1 (ja) * | 2002-12-26 | 2004-07-22 | Carna Biosciences Inc. | アルキニル基置換アザ糖誘導体およびそれを有効成分とする薬剤 |
| EP1594459B1 (en) | 2002-12-30 | 2010-02-17 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| EP1769071B1 (en) * | 2004-06-01 | 2011-07-27 | The Scripps Research Institute | Proteomic analysis |
| US7576222B2 (en) | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
| US7595327B2 (en) | 2005-03-21 | 2009-09-29 | Wyeth | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase |
| GT200600228A (es) | 2005-05-27 | 2006-12-26 | Inhibidores de la fosfolipasa a2 citosolica | |
| WO2008019284A1 (en) * | 2006-08-04 | 2008-02-14 | Decode Genetics Ehf | Phenoxymethylalkyne inhibitors of lta4h for treating inflammation |
| JP2011523659A (ja) * | 2008-06-02 | 2011-08-18 | シプラ・リミテッド | レボセチリジンの合成方法及びそれに使用する中間体 |
| HUE030114T2 (en) | 2010-07-08 | 2017-04-28 | Kaken Pharma Co Ltd | N-hydroxyformamide derivatives and pharmaceutical compositions containing them |
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028629A (en) * | 1990-03-28 | 1991-07-02 | Eli Lilly And Company | 5-Lipoxygenase inhibitors |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5552419A (en) | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| JPH10507158A (ja) | 1994-06-22 | 1998-07-14 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
| US5817822A (en) | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| KR980009238A (ko) | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
| EP0757984B1 (en) | 1995-08-08 | 2002-10-30 | Ono Pharmaceutical Co., Ltd. | Hydroxamic acid derivatives useful for inhibiting gelatinase |
| DE19542189A1 (de) | 1995-11-13 | 1997-05-15 | Hoechst Ag | Cyclische N-substituierte alpha-Iminohydroxamsäuren |
| DE59608740D1 (de) | 1995-11-13 | 2002-03-21 | Hoechst Ag | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren |
| ATE225779T1 (de) | 1995-11-17 | 2002-10-15 | Warner Lambert Co | Sulfonamidinhibitoren von matrix metalloproteinasen |
| ATE283264T1 (de) | 1995-12-08 | 2004-12-15 | Agouron Pharma | Zwischenprodukte zur herstellung von metallproteinasehemmern |
| US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| TW453995B (en) | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
| PT780386E (pt) * | 1995-12-20 | 2003-02-28 | Hoffmann La Roche | Inibidores de metaloprotease de matriz |
| WO1997024117A1 (en) * | 1996-01-02 | 1997-07-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds |
| CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
| NZ325939A (en) | 1996-01-23 | 2000-06-23 | Shionogi & Co | Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives |
| FR2748026B1 (fr) | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO1997045402A1 (fr) | 1996-05-24 | 1997-12-04 | Ono Pharmaceutical Co., Ltd. | Derives de phenylsulfonamide |
| NZ333825A (en) | 1996-07-22 | 2000-10-27 | Monsanto Co | Metalloprotease inhibitors particularly MMP-13 |
| PL331895A1 (en) | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
| HUP0000505A3 (en) | 1996-08-28 | 2001-12-28 | Procter & Gamble | Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them |
| IL128661A (en) | 1996-08-28 | 2001-10-31 | Procter & Gamble | Teleprotease inhibitors 1, 3 - diethocycles and pharmaceutical preparations containing them |
| KR20000035925A (ko) | 1996-08-28 | 2000-06-26 | 데이비드 엠 모이어 | 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드 |
| AU734834B2 (en) | 1996-08-28 | 2001-06-21 | Procter & Gamble Company, The | Heterocyclic metalloprotease inhibitors |
| ATE226193T1 (de) | 1996-08-28 | 2002-11-15 | Procter & Gamble | Substituierte zyklische amine als metalloproteaseinhibitoren |
| AU736134B2 (en) | 1996-10-16 | 2001-07-26 | Wyeth Holdings Corporation | Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| BR9712525A (pt) | 1996-10-16 | 1999-10-19 | American Cyanamid Co | O preparo e uso de ácidos orto-sulfonamido aril hidroxmicos como inibidores da metaloproteinase matricial e da tace |
| US5929097A (en) | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| WO1998016514A1 (en) | 1996-10-16 | 1998-04-23 | American Cyanamid Company | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| NZ335029A (en) | 1996-10-16 | 2000-10-27 | American Cyanamid Co | Ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase (MMP) and TACE (tumor necrosis factor, TNF, alpha converting enzyme) inhibitors |
| ATE212619T1 (de) | 1996-10-22 | 2002-02-15 | Upjohn Co | Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren |
| US6333324B1 (en) | 1996-12-17 | 2001-12-25 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine compounds as inhibitors of MMP or TNF |
| US5859061A (en) | 1997-01-17 | 1999-01-12 | Pharmacia & Upjohn Company | Bis-sulfonamides hydroxamic acids as MMP inhibitors |
| ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
| EP0960098A1 (en) | 1997-02-11 | 1999-12-01 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| SK115899A3 (en) * | 1997-02-27 | 2000-05-16 | American Cyanamid Co | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| DE69827940T2 (de) | 1997-03-04 | 2005-06-09 | Pharmacia Corp.(N.D.Ges.D.Staates Delaware) | Thiarylsulfonamid-hydroxamsäurederivate |
| GB9706255D0 (en) | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| WO1998043963A1 (en) | 1997-04-01 | 1998-10-08 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| CN1213021C (zh) * | 1998-02-19 | 2005-08-03 | 惠氏控股公司 | 作为基质金属蛋白酶抑制剂的 n －羟基－ 2 － (烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基 ) － 3 －取代的烷 |
| AU6542298A (en) | 1998-03-04 | 1998-09-22 | Monsanto Company | Thioaryl sulfonamide hydroxamic acid compounds |
-
2000
- 2000-01-27 WO PCT/US2000/001864 patent/WO2000044723A1/en active IP Right Grant
- 2000-01-27 US US09/492,686 patent/US6358980B1/en not_active Expired - Fee Related
- 2000-01-27 EP EP00904569A patent/EP1147085B1/en not_active Expired - Lifetime
- 2000-01-27 CN CNB008030170A patent/CN1178915C/zh not_active Expired - Fee Related
- 2000-01-27 BR BR0007784-4A patent/BR0007784A/pt not_active IP Right Cessation
-
2001
- 2001-07-26 NO NO20013678A patent/NO20013678L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1337948A (zh) | 2002-02-27 |
| EP1147085A1 (en) | 2001-10-24 |
| BR0007784A (pt) | 2002-02-05 |
| EP1147085B1 (en) | 2005-11-16 |
| WO2000044723A1 (en) | 2000-08-03 |
| NO20013678D0 (no) | 2001-07-26 |
| CN1178915C (zh) | 2004-12-08 |
| US6358980B1 (en) | 2002-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20013678D0 (no) | Alkynyl-holdige hydroksamsyre-derivater, deres fremstilling og deres anvendelse sommatriksmetalloproteinase(MMP)inhibitorer/TNF-<alfa>-konverteringsenzym(TACE)inhibitorer | |
| DK1144368T3 (da) | Acetyleniske alfa-aminosyrebaserede sulfonamid-hydroxamsyre-TACE-inhibitorer | |
| DK0938471T3 (da) | Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer | |
| DK1109787T3 (da) | Arylpiperaziner og deres anvendelse som metalloproteinaseinhiberende midler (MMP) | |
| AU2003282920A8 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| NO996491D0 (no) | 4-brom- eller 4-iod-fenylaminobenzhydroksamsyre-derivater og deres anvendelse som MEK-inhibitorer | |
| NO20014135L (no) | Nye sulfonamidforbindelser og deres anvendelse | |
| NO971537D0 (no) | Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser | |
| ATE325791T1 (de) | Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren | |
| DK1036062T3 (da) | Hydroxamsyrederivater som matrix metalloprotease (MMP) inhibitorer | |
| AU2003220401A8 (en) | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases | |
| NO991922L (no) | Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer | |
| ATE260251T1 (de) | Hydroxamsäurederivate als matrix- metalloproteinase-inhibitoren | |
| DK1147080T3 (da) | Alkynylholdige hydroxamsyreforbindelser som TACE-inhibitorer | |
| NO20023951D0 (no) | Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler | |
| AU2202101A (en) | Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors | |
| IL144345A0 (en) | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors | |
| BR0007278A (pt) | Inibidores de hidroxamato reverso demetalo-proteinases de matriz | |
| NO20013639L (no) | Acetyleniske <beta>-sulfonamido- og -fosfinsyreamid- hydroksamsyre-TACE-inhibitorer | |
| DZ3463A1 (fr) | Cristaux d'inhibiteurs de l'echangeur sodium-hydrogene de type 1 | |
| DK1157024T3 (da) | Acetyleniske ortho-sulfonamido- og phosphinsyreamido-bicykliske heteroarylhydroxamsyrer som TACE-inhibitorer | |
| ATE261955T1 (de) | Heteroarylderivate mit acetylengruppen enthaltenden sulfonamid- und phosphinsäureamid- hydroxamsäurederivaten als tace inhibitoren | |
| AU2003304456A1 (en) | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | |
| DK0993439T3 (da) | 4-brom- eller 4-iod-phenyl-amino-benzhydroxamsyrederivater og deres anvendelse som MEK inhibitorer | |
| AU2002359347A1 (en) | Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |